NCI clinical trial leads to atezolizumab approval for advanced alveolar soft part sarcoma 🔗 Access full article via NCI News ReleasesThe immunotherapy drug atezolizumab ( Tecentriq ) to treat advanced alveolar soft part sarcoma has received FDA approval following a clinical trial led by NCI. Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
